SynthesisNeurosurgical review2026
Treatment outcomes of stereotactic radiosurgery for thyroid cancer spine metastases-systematic review.
Synthesis in Neurosurgical review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Outcomes of stereotactic radiosurgery for spine multiple myeloma-a systematic review.Neurosurgical review · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spinal metastases from thyroid carcinoma (TCSMs) are uncommon but clinically challenging, often occurring in patients with relatively long survival. The role of stereotactic radiosurgery (SRS) in managing TCSMs has been defined. We performed a systematic review to evaluate the efficacy, safety, and outcomes of SRS for TCSMs. A systematic literature search was conducted using PubMed/MEDLINE, Scopus, and Embase databases. Of 474 records identified, 432 studies underwent title and abstract screening after duplicate removal. Eleven articles were reviewed in full, and four studies met the inclusion criteria. Extracted data included patient demographics, thyroid cancer histology, spinal metastasis characteristics, prior treatments, SRS treatment parameters, clinical outcomes [local tumor control (LTC), overall survival (OS), pain response], treatment-related toxicity, and prognostic factors. Across included studies, SRS was delivered using heterogeneous dose and fractionation schemes, most commonly single-fraction regimens ranging from 12 to 24 Gy, with hypofractionated schedules delivering 18–30 Gy. Median follow-up ranged from 15 to 29 months. Overall, LTC ranged from 72% to 91%. One-, two-, and three-year LTC rates ranged from 67 to 96%, 56–89%, and 34–79%, respectively, with a reported 5-year LTC of 82% in one study. Median OS ranged from 28.9 to 43 months, with 1- and 2-year OS rates of 55–86% and 44–74%, respectively. Pain outcomes generally improved or remained stable following SRS. Treatment-related toxicity was infrequent and predominantly low grade, including dysphagia, esophagitis, radiculopathy, pain flare, vertebral compression fracture, and rare esophageal stenosis. Factors associated with improved outcomes included younger age, lower Bilsky score, non-papillary histology, prior radiation therapy, controlled extra-spinal disease, and multifraction SRS. SRS provides effective and durable local control for TCSMs with acceptable toxicity. Favorable survival outcomes reflect the radiosensitive nature of thyroid cancer and the prolonged survival of this patient population.
Indexed as
Identifiers
41896393What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.